Nexus Pharmaceuticals Announces FDA Approval of Dicyclomine HCl Injection, USP

by Patrick Weeks

Lincolnshire, Ill., February 14, 2019 — Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in 20mg/2mL vial, the generic equivalent to Bentyl®. Dicyclomine HCl, USP, is currently listed on the American Society of Health-System Pharmacists’ drug shortage list.

“The addition of Dicyclomine Injection to our portfolio of products is another example of our commitment to provide medicines in shortage situations in convenient presentations,” said Omair Ahmed, Chief Commercial Officer, Nexus Pharmaceuticals Inc.

Dicyclomine HCL Injection is immediately available in cartons of five single dose vials, each containing 20mg of Dicyclomine. It is Latex and Preservative free.

For wholesaler information, please visit the product page.

About Dicyclomine HCL Injection

Dicyclomine Hydrochloride Injection, USP is an antispasmodic and anticholinergic (antimuscarinic) agent indicated for the treatment of functional bowel/irritable bowel syndrome.

About Nexus Pharmaceuticals Inc.

Nexus Pharmaceuticals Inc., a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.

*Bentyl is a registered trademark of Aptalis Pharma US, Inc.


Nexus Pharmaceuticals Inc.
Zoya Ahmed

<  Read More Articles
React transport logo image only